Holen Sie sich die Stockscreener-App
2.22
0.91%
0.02
Handel nachbörslich:
2.22
Schlusskurs vom Vortag:
$2.20
Offen:
$2.24
24-Stunden-Volumen:
27,760
Relative Volume:
0.62
Marktkapitalisierung:
$3.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.38M
KGV:
-0.4436
EPS:
-5.0046
Netto-Cashflow:
$-12.45M
1W Leistung:
-9.39%
1M Leistung:
+6.99%
6M Leistung:
-53.56%
1J Leistung:
-88.17%
1-Tages-Spanne:
$2.20
$2.33
1-Wochen-Bereich:
$2.1501
$2.55
52-Wochen-Spanne:
$1.70
$26.47
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Firmenname
Avenue Therapeutics Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Park Avenue Securities LLC Reduces Position in Morningstar, Inc. (NASDAQ:MORN) - Defense World
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Avenue Therapeutics To Participate In Maxim Group’s 2024 Healthcare Virtual Summit - Barchart
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
Forest Avenue Capital Management LP Has $24.54 Million Holdings in GE Vernova Inc. (NYSE:GEV) - Defense World
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
First Avenue IPO on Nomu 740% oversubscribed; offer price set at SAR 6 - بوابة أرقام المالية
Avenue Supermart shares down 0.27% as Nifty gains - The Economic Times
Avenue Supermart shares fall 0.27 per cent in Thursday's trading session - The Economic Times
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Avenue Supermart shares up 0.35% as Nifty gains - The Economic Times
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
2 Dead In Series Of Police Shootouts That Shut Down Victory Boulevard - Patch
Meet Microsoft’s new COO—a former superstar CFO from GE - Fortune
Share price of Avenue Supermart rises as Nifty strengthens - The Economic Times
Allarity Therapeutics appoints new CFO - Investing.com India
Allarity Therapeutics expands ATM agreement, appoints new CFO - Investing.com
Allarity Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Allarity Therapeutics Names Alex Epshinsky Finance Chief - MarketWatch
Allarity appoints Alex Epshinsky as CFO - TipRanks
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - The Malaysian Reserve
New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways - ACS Publications
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avenue Therapeutics Inc-Aktie (ATXI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
| Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
353,000 |
49,600 |
22,000 |
| Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
264,000 |
36,960 |
681,000 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):